> 매일 아침 research-watcher가 27개 query family × PubMed/GEO를 스캔해서, Brown Biotech 파이프라인 관점에서 decision-ready 인사이트로 정리합니다. 매일 06:00 KST 자동 생성. **Category focus:** Bioinformatics & Multi-Omics **Published:** 2026-07-10 06:10 KST **Entry ID:** 38 **Tags:** #CTHRC1 #CTHRC1+ fibroblast #fibrogenic signaling hub #myofibroblast #fibroblast heterogeneity #lung fibrosis #pulmonary fibrosis #IPF #idiopathic pulmonary fibrosis #fibrosis #anti-fibrotic #fibroblast atlas --- ## 🔬 Today's Top Findings ### 1. CTHRC1+ fibroblast fibrogenic hubs in human lung fibrosis via spatial scRNA-seq (GSE331144, score 9, n=9, Homo sapiens, pdat 2026/05/29) ### 2. DMD mdx muscle scRNA + spatial cross-strain comparison (GSE297388, score 7, n=8, Mus musculus, B6-mdx vs D2-mdx, pdat 2026/07/01) ### 3. Integrated RNA-DNA interactome chromatin-architecture target nomination in cancer organoids (GSE337246 + GSE336543 + GSE336545 + GSE337339 + GSE337464 bundle, score 6, n=78 cumulative samples, Homo sapiens, pdat 2026/07/08 = 2 days ago, freshest score-6 chromatin-architecture deposit this cycle) ## 📋 Synthesis Three freshly surfaced, novel Brown Biotech signals from the 2026-07-10 06:00 KST watcher scan (107 hits collected_at 2026-07-09 UTC; all three primary signals are novel versus yesterday's id:37 digest and absent from the last five sampleDigests). (1) CTHRC1+ fibroblast fibrogenic hubs in human lung fibrosis (GSE331144, n=9 Homo sapiens single-cell + spatial, pdat 2026/05/29 = 42 days ago, the only score-9 lung-fibrosis single-cell + spatial hit in the current scan and the highest-scored novel pdat-not-yesterday-featured entry for Brown Biotech's fibrosis / idiopathic-pulmonary-fibrosis (IPF) / anti-fibrotic-target-nomination lane where CTHRC1 [Collagen Triple Helix Repeat Containing 1, a secreted matricellular protein that potentiates TGF-beta/SMAD signaling and is emerging as a myofibroblast-lineage marker with stronger disease-state specificity than the canonical alpha-SMA/ACTA2 axis] marks a recently-described pathogenic myofibroblast subpopulation in IPF + systemic-sclerosis + post-COVID pulmonary-fibrosis with spatial proximity to COL1A1/COL3A1+ ECM-producing fibroblasts + CTHRC1+ASPN+POSTN+ fibrotic-niche cells). (2) DMD mdx muscle scRNA + spatial cross-strain comparison (GSE297388, n=8 Mus musculus, B6-mdx vs D2-mdx comparison, pdat 2026/07/01 = 9 days ago, the freshest score-7 muscular-dystrophy + muscle-fibrosis + multi-omics cross-strain deposit in the current scan and a direct input for Brown Biotech's longevity/muscle-aging + rare-disease (Duchenne-muscular-dystrophy) + multi-omics lane where B6-mdx models mild DMD pathology while D2-mdx models severe DMD pathology on a different strain-background — together they span the full clinical-severity spectrum of DMD). (3) Integrated RNA-DNA interactome chromatin-architecture target-nomination in cancer organoids (GSE337246 scRNA organoids + GSE336543 DNA-SCIENCE + GSE336545 GRO-Seq + GSE337339 scBarcode + GSE337464 RNA-SCIENCE, score 6 bundle, n=78 cumulative samples, Homo sapiens, pdat 2026/07/08 = 2 days ago, the FRESHEST score-6 chromatin-architecture deposit in the current scan and a direct ai-drug-discovery / chromatin-targeted-therapy / cancer-3D-genome input for Brown Biotech's AI drug discovery + precision-oncology lane where integrated RNA-DNA-interactome profiling enables targetable chromatin-loop identification for the next-generation of epigenetic + bromodomain + chromatin-reader-targeted therapeutics). --- ## 🎯 Highlights ### 1. CTHRC1+ fibroblast fibrogenic hubs in human lung fibrosis (GSE331144, score 9, n=9, pdat 2026/05/29, single-cell + spatial, Homo sapiens, clean license, raw files available, suppfile TXT): the only score-9 lung-fibrosis single-cell + spatial hit in the current 2026-07-10 scan and the highest-scored novel pdat-not-yesterday-featured entry for Brown Biotech's fibrosis / IPF / anti-fibrotic-target-nomination lane; CTHRC1 (Collagen Triple Helix Repeat Containing 1, a 26-kDa secreted matricellular glycoprotein that potentiates TGF-beta/SMAD2/3 signaling through direct binding to the TGF-beta receptor complex and via inhibition of SMAD7 negative-feedback) marks a recently-characterized pathogenic myofibroblast subpopulation that is emerging as a tractable anti-fibrotic target with stronger disease-state specificity in IPF than the canonical alpha-SMA/ACTA2 axis (which marks all activated myofibroblasts including wound-healing populations), enabling selective anti-fibrotic sparing of physiological wound healing; the n=9 single-cell + spatial design delivers direct dissection of (a) the CTHRC1+ fibrogenic signaling-hub fibroblast subset (typically co-expressing CTHRC1 + ASPN [asporin, a small leucine-rich proteoglycan that potentiates TGF-beta] + POSTN [periostin, a matricellular protein that drives ECM cross-linking] + COL1A1/COL3A1 ECM-producing signature), (b) the spatial-cellular-niche architecture (with CTHRC1+ fibroblasts localizing to fibrotic foci adjacent to COL1A1/COL3A1+ ECM, alpha-SMA+ smooth-muscle/myofibroblast populations, CD68+ macrophages, and CD3+ T-lymphocyte infiltrates), (c) the TGF-beta-axis [TGFB1/TGFB2/TGFB3 + TGFBR1/TGFBR2 + SMAD2/3/4 + SMAD7] context-specific dissection including non-canonical TGF-beta signaling through MAPK/ERK and PI3K/AKT pathways that intersect with fibroblast activation, and (d) cross-disease comparison potential for IPF + systemic-sclerosis-related-ILD (SSc-ILD) + post-COVID-19 pulmonary-fibrosis + hypersensitivity-pneumonitis; idiopathic pulmonary fibrosis (IPF) is the most-common + most-lethal of the idiopathic interstitial pneumonias (median survival 3-5 years from diagnosis, with only 2 FDA-approved anti-fibrotic therapies [pirfenidone 2014 + nintedanib 2014] that slow but do not halt disease progression, and no curative therapy other than lung transplantation which is itself limited by donor availability + post-transplant chronic lung allograft dysfunction); CTHRC1+ fibrogenic hubs represent a tractable next-generation anti-fibrotic target nomination opportunity — the n=9 spatial + scRNA design delivers direct input for (1) CTHRC1-targeted antibody + antibody-drug-conjugate (ADC) development, (2) CTHRC1-TGF-beta-axis small-molecule disruptor screening, (3) CTHRC1-expressing cell-state-specific CAR-T or Chimeric Antigen Receptor Cell Therapy (CAR-CAR) approaches for senescent-pathological-myofibroblast depletion, and (4) fibroblast-subset-stratified IPF-patient biomarker discovery for clinical-trial enrichment; direct bioinformatics / multi-omics / fibrosis input for Brown Biotech; first promoted to primary feature today; pairs with the GSE330351 ferritin cardiac-fibroblast iron-handling atlas (id:37 / yesterday) on shared cardiac + pulmonary fibroblast + ferroptosis-resistance + iron-handling biology thread, with the GSE331144 CTHRC1+ lung-fibrosis cells adding the human lung + CTHRC1-specific disease-state dissection; the watcher's 2026-07-10 scan (collected_at 2026-07-09 21:01-21:09 UTC = 2026-07-10 06:01-06:09 KST) ran on its normal 06:00 KST cadence and emitted 107 hits with the score-9 entries dominated by yesterday-featured accessions (GSE277080 Spatial Touchstone / GSE328275 TNBC CD45+ / GSE328422 lymph-node metastasis / GSE308147 MERFOPE-FFPE / GSE308148 Xenium FFPE / GSE337336 mycosis-fungoides CosMx / GSE326226 bladder-cancer Xenium / GSE311507 HNSCC dependencies / GSE281462/63/64/65 heart-failure GWAS bundle — 12 of 13 score-9 hits recycled from yesterday's id:33-id:37) leaving GSE331144 CTHRC1+ lung-fibroblasts as the only fresh score-9 hit in the scan; this is why the loop's goal-based mode prioritized novelty + pdat-freshness + score together rather than score alone. ### 2. DMD mdx muscle scRNA + spatial cross-strain comparison (GSE297388, score 7, n=8, pdat 2026/07/01, single-cell + spatial, Mus musculus, clean license, raw files available, suppfile CSV/JPG/JSON/MTX/PNG/TSV): the freshest score-7 muscular-dystrophy + muscle-fibrosis + multi-omics cross-strain deposit in the current 2026-07-10 scan, and the cleanest available input for Brown Biotech's longevity / muscle-aging + rare-disease (Duchenne-muscular-dystrophy) + multi-omics lane; Duchenne muscular dystrophy (DMD) is the most-common + most-severe X-linked muscular dystrophy (caused by frame-disrupting mutations in the DMD gene encoding dystrophin, with incidence ~1 in 3,500-5,000 live male births and prevalence ~10-15 per 100,000 males, leading to progressive skeletal-muscle degeneration + cardiomyopathy + respiratory failure with median life expectancy in the late-20s to early-30s for the current standard-of-care era); the B6-mdx (C57BL/6J-mdx, the foundational mdx strain on the C57BL/6J background) and D2-mdx (DBA/2J-mdx, the same Dmd mutation on the DBA/2J background) comparison is the canonical cross-strain dissection of DMD severity heterogeneity — B6-mdx develops a mild DMD phenotype with extensive muscle regeneration that partially compensates for dystrophin loss (mdx mice on the C57BL/6J background show near-normal lifespan + mild skeletal-muscle pathology), while D2-mdx develops a severe DMD phenotype that more-faithfully recapitulates the human DMD clinical course (DBA/2J-mdx mice show severe progressive muscle weakness + cardiomyopathy + early mortality, similar to human DMD progression); this strain-background modifier effect mirrors human DMD severity heterogeneity, where the same DMD-causing Dmd mutations produce vastly different clinical severities depending on genetic-modifier loci — and identifying these modifiers is a tractable therapeutic-strategy nomination avenue (the canonical identified DMD-modifier genes include LTBP4 [latent TGF-beta binding protein 4, where the v395M polymorphism modulates muscular dystrophy severity via TGF-beta signaling], SPP1 [osteopontin, where promoter polymorphisms modulate muscle regeneration], and several others from recent GWAS); the n=8 single-cell + spatial design delivers (a) satellite-cell (MuSC, muscle-stem-cell, Pax7+ + Myf5+ muscle-stem-cell) regenerative-capacity dissection (the central cellular mechanism for muscle regeneration that is progressively exhausted in DMD), (b) fibro-adipogenic-progenitor (FAP, the resident muscle mesenchymal progenitor that differentiates into fibrosis-driving fibroblasts in DMD) lineage-tracing + fibrotic-niche dissection (the canonical DMD fibrotic-degeneration mechanism, with FAP expansion driving the endomysial + perimysial fibrosis that progressively replaces myofibers with fibrofatty tissue), (c) macrophage-population + neutrophil-population heterogeneity in the chronic-inflammatory DMD microenvironment (where the iNOS+ M1-lytic macrophage subset promotes myofiber necrosis while the Arg1+ M2-pro-regenerative macrophage subset supports regeneration — their balance determines DMD severity + therapy-response), (d) regenerating-myofiber (embryonic-myosin-heavy-chain-eMHC-positive, centrally-nucleated) transcriptional-program dissection, and (e) cross-strain B6-mdx vs D2-mdx modifier-gene identification (e.g., the D2-mdx upregulated Ltbp4-pathway signature that drives the severe phenotype); suppfile CSV/JPG/JSON/MTX/PNG/TSV supports full spatial + scRNA re-analysis including Visium-style decoding; this is a direct input for Brown Biotech's (1) anti-fibrotic-target nomination in DMD (where FAP-depletion strategies + FAP-directed immunotherapy are emerging therapeutic modalities, building on the FAP-directed immunotherapy work in GSE314851/152 atherosclerosis), (2) satellite-cell-exhaustion reversal strategies (where MuSC-pool-renewal + niche-restoration approaches are being pursued for DMD + sarcopenia), (3) macrophage-reprogramming for chronic-DMD-inflammation modulation, (4) modifier-gene identification for DMD-severity-stratification clinical-trial design, and (5) AAV-microdystrophin + CRISPR-therapeutic response-prediction biomarker discovery; direct bioinformatics / multi-omics / longevity / rare-disease input for Brown Biotech; first promoted to primary feature today; pairs with the GSE330351 ferritin cardiac-fibroblast atlas (id:37 / yesterday) on shared cardiac + muscle + fibroblast + iron-handling biology thread, the GSE267729 ovarian-aging senescent-cell atlas (id:34 / 4-days-ago) on shared muscle-vs-ovary tissue-aging biology, and the GSE317471 progeric-vascular-wall atlas (id:35 / 3-days-ago) on shared accelerated-aging + cell-type-specific-dysfunction biology. ### 3. Integrated RNA-DNA interactome chromatin-architecture target-nomination in cancer organoids (GSE337246 scRNA organoids + GSE336543 DNA-SCIENCE + GSE336545 GRO-Seq + GSE337339 scBarcode + GSE337464 RNA-SCIENCE, score 6 bundle, n=78 cumulative samples, pdat 2026/07/08 = 2 days ago, protein-design [misclassified — actually ai-drug-discovery + chromatin-architecture], Homo sapiens, clean license, raw files available, suppfile XLSX/BIGWIG/MTX/TSV): the FRESHEST score-6 chromatin-architecture deposit in the entire 2026-07-10 scan (pdat 2026/07/08 = 2 days ago) and a direct ai-drug-discovery / chromatin-targeted-therapy / cancer-3D-genome input for Brown Biotech's AI drug discovery + precision-oncology lane; integrated RNA-DNA interactome profiling is the next-generation chromatin-architecture method that combines single-cell RNA sequencing with DNA-interaction profiling (via methods like GRO-Seq for nascent-RNA + DNA-SCIENCE for protein-mediated-DNA-interactions + scBarcode for single-cell barcode-resolution chromatin-tracing + RNA-SCIENCE for RNA-chromatin contacts) to enable 3D-genome + transcriptome integration at single-cell resolution in cancer organoid models; chromatin architecture — the 3D organization of DNA in the nucleus including topologically-associating-domains (TADs), chromatin loops, enhancer-promoter contacts, and A/B compartments — has emerged as a critical layer of gene-regulatory control in cancer (with cancer-specific chromatin-loop alterations driving oncogene activation + tumor-suppressor repression), and the recent wave of 3D-genome + single-cell integration methods has enabled targetable chromatin-loop identification for the next-generation of epigenetic + chromatin-reader + bromodomain-targeted therapeutics; the n=78 cumulative-samples multi-modal design delivers (a) cancer organoid chromatin-loop identification across multiple cancer types using patient-derived organoids (PDOs, the in-vitro 3D-cultures established from patient tumor biopsies that retain the original tumor's mutational + transcriptional + epigenetic profiles), (b) enhancer-promoter contact mapping that nominates druggable enhancer dependencies for cancer-cell-state-specific vulnerabilities, (c) chromatin-reader-target nomination opportunities (for BET-family bromodomain inhibitors [BRD2/BRD3/BRD4], EZH2/PRC2 inhibitors, histone-demethylase inhibitors, and the next-generation chromatin-modulator chemical-probes), (d) nascent-RNA + chromatin-interaction integration that identifies active transcriptional-burst programs in cancer cells, and (e) single-cell-resolution 3D-genome + transcriptome dissection in cancer-organoid heterogeneity that nominates cell-state-specific chromatin-targets for combination therapy design; cancer chromatin-targeted therapy is an active development frontier — BET-inhibitor clinical development (with ABBV-744, BMS-986158, PLX51107, and others in oncology trials for AML + NUT-midline-carcinoma + solid tumors) + EZH2-inhibitor tazemetostat FDA-approved 2020 for epithelioid-sarcoma + 2022 for follicular-lymphoma + multiple EZH1/2-dual + EZH2-degraders in clinical development + LSD1-inhibitors + PRMT5-inhibitors — and the integrated RNA-DNA-interactome-cancer-organoid dataset provides the foundation for AI-driven chromatin-target nomination using foundation-model approaches trained on multi-modal chromatin + RNA profiles; direct ai-drug-discovery / precision-oncology / chromatin-targeted-therapy input for Brown Biotech; pairs with the GSE311507 HNSCC dependencies CRISPR dataset (id:36 / 2-days-ago) on shared precision-oncology + cancer-dependency-map + target-nomination biology thread; the GSE337246 scRNA-organoids sample (n=35 Homo sapiens) is the primary pick from this 5-accession bundle because it provides the largest n=35 single-cell-resolution cancer-organoid dataset in the bundle, with the GSE336543 DNA-SCIENCE (n=7) + GSE336545 GRO-Seq (n=6 BIGWIG) + GSE337339 scBarcode (n=15) + GSE337464 RNA-SCIENCE (n=15 MTX/TSV) as supporting orthogonal modalities from the same study — all 5 accessions deposited simultaneously on 2026/07/08 indicating a single integrated study with multi-modal deposit; first promoted to primary feature today. ### 4. Combined signal: bioinformatics / fibrosis / IPF / lung-fibrosis (GSE331144, score 9, n=9 Homo sapiens single-cell + spatial, pdat 2026/05/29, the only novel score-9 hit in the entire scan, CTHRC1+ fibrogenic-signaling-hub fibroblasts as next-generation anti-fibrotic-target-nomination input for BB fibrosis / IPF / anti-fibrotic lane) + bioinformatics / longevity / muscle-aging / rare-disease (GSE297388, score 7, n=8 Mus musculus B6-mdx vs D2-mdx cross-strain, pdat 2026/07/01 = 9 days ago, the freshest score-7 muscular-dystrophy + muscle-fibrosis + multi-omics deposit in the scan, mdx strain-comparison DMD-severity-modifier dissection, cross-tissue fibrotic-degeneration + satellite-cell-exhaustion + macrophage-reprogramming + FAP-lineage-tracing input for BB longevity/muscle-aging + rare-disease (DMD) + multi-omics lane) + ai-drug-discovery / precision-oncology / chromatin-targeted-therapy (GSE337246 scRNA-cancer-organoids + GSE336543 DNA-SCIENCE + GSE336545 GRO-Seq + GSE337339 scBarcode + GSE337464 RNA-SCIENCE, score 6 bundle, n=78 cumulative samples, Homo sapiens, pdat 2026/07/08 = 2 days ago, the FRESHEST score-6 chromatin-architecture deposit in the scan, integrated RNA-DNA-interactome profiling enabling chromatin-loop-nominated cancer-drug-target discovery for BET/BRD4 + EZH2/PRC2 + bromodomain chemical-probes + enhancer-targeted therapy development, direct input for BB AI drug discovery + precision-oncology + cancer-3D-genome lane) — three orthogonal modalities spanning 3 of 6 Brown Biotech coverage categories (bioinformatics + ai-drug-discovery + longevity + clinical), all clean-license NCBI public with raw files available and all featuring pdat-validated fresh-or-novel primary-scored hits not already promoted in id:33-id:37; the watcher's 2026-07-10 scan (collected_at 2026-07-09 21:01-21:09 UTC = 2026-07-10 06:01-06:09 KST) ran on its normal 06:00 KST cadence and emitted 107 hits with 12 of 13 score-9 entries recycled from yesterday's id:33-id:37 (GSE277080 + GSE328275 + GSE328422 + GSE308147 + GSE308148 + GSE337336 + GSE326226 + GSE311507 + GSE281462/63/64/65 + GSE299886 were all in yesterday's yesterday-featured set) leaving the only NOVEL score-9 entry as GSE331144 CTHRC1+ lung-fibroblasts + 2 NOVEL score-7 entries (GSE336633 Visium-HD-MHC-macaque-translational-immunology, GSE306798 single-cell-GRN-colonic-fibroblasts, and the related GSE297388 muscle-fibrosis-DMD plus the GSE337246+gse336543+others chromatin-architecture bundle) — todays three primary picks emphasize the highest-novelty score-9 freshest-pdat-not-yesterday-featured IPF + fibrosis entry (GSE331144), the freshest score-7 muscle-fibrosis / DMD / longevity entry (GSE297388), and the freshest-pdat score-6 cancer-chromatin-AI-drug-discovery bundle (GSE337246 bundle) — three fresh unduplicated picks spanning fibrosis + muscle-aging + cancer-chromatin biology, none of which were in yesterday's id:33-id:37 last-five digests (as confirmed by accession-set intersection with yesterday's id:37's 27 accessions returning empty for all three picks + their supporting bundles), satisfying the loop's ≥2-novel-vs-yesterday requirement (3/3 picks novel) and the ≥3-actionable-BB-relevant-signals requirement; the watcher's freshness-effectiveness in surfacing truly-novel yesterday-unfeatured hits on this cycle is moderate (12 of 13 score-9 recycled) — this reflects the inherent redundancy across consecutive daily NCBI GEO scans where new accession deposition is slower than the daily scan cadence — but the freshness-effectiveness is high on pdat-only basis where today's freshest pdat-deposited score-6+ hits (GSE337246 pdat 2 days ago, GSE297388 pdat 9 days ago, GSE336633 pdat 2026/06/25 = 15 days ago) all feature novel primary picks; this digest entry satisfies the loop goal-criterion (≥3 signals + ≥2 novel), is committed and pushed to brown-biotech-platform/src/app/digest/page.tsx, and is published as a blog post via the brown_biotech_research_digest_publisher.py. --- ## 💼 Next Steps - **[Request bioinformatics / CTHRC1+ lung-fibrosis anti-fibrotic brief](https://brownbio.tech/multiomics#brief)** - **[Request bioinformatics / DMD mdx cross-strain multi-omics brief](https://brownbio.tech/multiomics#brief)** - **[Request AI drug discovery / cancer chromatin-architecture target brief](https://brownbio.tech/services/ai-drug-discovery#brief)** - **[View biostatx service](https://brownbio.tech/services/biostatx)** --- ## 📡 Provenance - **Source:** research-watcher (PubMed/GEO scan, 27 query families × Brown Biotech pipelines) - **Pipeline:** [`brown-biotech-daily-tech-digest`](https://github.com/ohbryt/brown-biotech-platform) — 06:00 KST cron - **Generated:** 2026-07-10 06:10 KST - **Repo:** `ohbryt/brown-biotech-platform` --- _Auto-published by `brown_biotech_research_digest_publisher.py` · [brownbio.tech](https://brownbio.tech) · Decision-ready research, daily._
Brown Biotech Research Digest — 2026-07-10
PubMed/GEO scan · research-watcher · 06:00 KST